Hyperion Therapeutics Report issue

Contributed to NME For profit Phase 3
Founded: South San Francisco CA United States (2006)
Status: Acquired by Horizon Pharma (2015) → now Amgen

Organization Overview

First Clinical Trial
2011
NCT01347073
First Marketed Drug
2013
glycerol phenylbutyrate (ravicti)
First NDA Approval
2013
glycerol phenylbutyrate (ravicti)
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

glycerol phenylbutyrate (ravicti) (2013 NDA)

Drugs in Phase 3 Trials (2)

Key: Hyperion Therapeutics (1) Acquired (1)

diapep277 (4 trials)

glycerol phenylbutyrate (ravicti) (1 trial)

Indications

Approved Indications


 

Urea Cycle Disorders, Inborn

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 3)

Urea Cycle Disorders, Inborn (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2